Nicorandil reduces myocardial infarct size by opening the KATP channel in rabbits

被引:43
作者
Ohno, Y
Minatoguchi, S
Uno, Y
Kariya, T
Arai, M
Yamashita, K
Fujiwara, T
Fujiwara, H
机构
[1] Gifu Univ, Sch Med, Dept Internal Med 2, Gifu 500, Japan
[2] Kyoto Womens Univ, Kyoto, Japan
关键词
nicorandil; infarct size; rabbit; plasma nicorandil concentration; KATP channel;
D O I
10.1016/S0167-5273(97)00270-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We examined whether nicorandil reduces myocardial infarct size (1) when administered before ischemia, and (2) when administered before reperfusion, and whether (3) infarct size is influenced by the plasma nicorandil concentration and the opening of the KATP channel. Anesthetized open-chest Japanese white male rabbits were subjected to a 30 min coronary occlusion (ischemia) and a 48 h reperfusion in the following six groups; Group 1 (n=9): control group, Group 2 (n=9): pre-ischemia to post-reperfusion group (nicorandil 10 mu g/kg/min, i.v.), Group 3 (n=7): pre-ischemia to post-reperfusion+glibenclamide group (glibenclamide 0.3 mu g/kg, i.v.+micorandil 10 mu g/kg/min, i.v.), Group 4 (n=8): pre-reperfusion to post-reperfusion group (nicorandil 10 mu g/kg/min, i.v.), Group 5 (n=8): pre-ischemia low-dose group (nicorandil 10 mu g/kg/min for 5 min i.v.), Group 6 (n=7): pre-ischemia high-dose group (nicorandil 100 mu g/kg/min for 5 min i.v.). The plasma nicorandil concentrations were measured from blood samples taken immediately before the ischemia. After the 48 h reperfusion, the size of the infarct was measured histologically with immunohistochemical actin staining and expressed as a percentage of the area at risk. Results: Infarct sizes were as follows; Group 1 (control): 41.0+/-3.5%, Group 2: 31.3+/-2.0% (P<0.05 vs. control), Group 3: 40.9+/-3.4%, Group 4: 45.2+/-4.4%, Group 5: 35.8+/-3.3%, Group 6: 25.2+/-3.9% (P<0.05 vs. control). Infarct size was inversely correlated with the plasma nicorandil concentrations (y=-0.031x+41.0, r=0.65, P<0.05). Conclusions: The pre-ischemic but not post-ischemic administration of nicorandil reduced the size of myocardial infarct by opening the KATP channels, and this effect was dependent on the plasma nicorandil concentrations immediately before the ischemia induced in rabbits. (C) 1997 Elsevier Science Ireland Ltd.
引用
收藏
页码:181 / 190
页数:10
相关论文
共 16 条
  • [1] AUCHAMPACH JA, 1992, J CARDIOVASC PHARM, V20, P765, DOI 10.1097/00005344-199211000-00012
  • [2] REDUCTION OF SIZE OF MYOCARDIAL-INFARCTION WITH NICORANDIL, A NEW ANTIANGINAL DRUG, AFTER CORONARY-ARTERY OCCLUSION IN DOGS
    ENDO, T
    NEJIMA, J
    KIUCHI, K
    FUJITA, S
    KIKUCHI, K
    HAYAKAWA, H
    OKUMURA, H
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1988, 12 (05) : 587 - 592
  • [3] CARDIOPROTECTIVE EFFECTS OF NICORANDIL
    GROSS, GJ
    AUCHAMPACH, JA
    MARUYAMA, M
    WARLTIER, DC
    PIEPER, GM
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1992, 20 : S22 - S28
  • [4] BLOCKADE OF ATP-SENSITIVE POTASSIUM CHANNELS PREVENTS MYOCARDIAL PRECONDITIONING IN DOGS
    GROSS, GJ
    AUCHAMPACH, JA
    [J]. CIRCULATION RESEARCH, 1992, 70 (02) : 223 - 233
  • [5] GROSS GJ, 1993, EUR HEART J SB, V14, P10
  • [6] NICORANDIL IMPROVES POSTISCHEMIC CONTRACTILE FUNCTION INDEPENDENTLY OF DIRECT MYOCARDIAL EFFECTS
    GROVER, GJ
    SLEPH, PG
    PARHAM, CS
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 15 (05) : 698 - 705
  • [7] HESTER RK, 1985, J PHARMACOL EXP THER, V233, P100
  • [8] EFFECT OF NICORANDIL ON POSTISCHEMIC CONTRACTILE DYSFUNCTION IN THE HEART - ROLES OF ITS ATP-SENSITIVE K+ CHANNEL OPENING PROPERTY AND NITRATE PROPERTY
    IWAMOTO, T
    MIURA, T
    URABE, K
    ITOYA, M
    SHIMAMOTO, K
    IIMURA, O
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1993, 20 (09) : 595 - 602
  • [9] PHARMACOLOGY AND THERAPEUTIC EFFECTS OF NICORANDIL
    KINOSHITA, M
    SAKAI, K
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 1990, 4 (04) : 1075 - 1088
  • [10] EFFECTS OF NICORANDIL AND NIFEDIPINE ON PROTECTION OF ISCHEMIC MYOCARDIUM
    LAMPING, KA
    CHRISTENSEN, CW
    PELC, LR
    WARLTIER, DC
    GROSS, GJ
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1984, 6 (03) : 536 - 542